ATE529444T1 - Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten - Google Patents

Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten

Info

Publication number
ATE529444T1
ATE529444T1 AT04022346T AT04022346T ATE529444T1 AT E529444 T1 ATE529444 T1 AT E529444T1 AT 04022346 T AT04022346 T AT 04022346T AT 04022346 T AT04022346 T AT 04022346T AT E529444 T1 ATE529444 T1 AT E529444T1
Authority
AT
Austria
Prior art keywords
kunitz domains
human plasmin
inhibitors derived
plasmin inhibitors
nucleic acids
Prior art date
Application number
AT04022346T
Other languages
English (en)
Inventor
William Markland
Robert Charles Ladner
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of ATE529444T1 publication Critical patent/ATE529444T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/515—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics
    • C04B35/58—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides
    • C04B35/584—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride
    • C04B35/593—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride obtained by pressure sintering
    • C04B35/5935—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride obtained by pressure sintering obtained by gas pressure sintering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
AT04022346T 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten ATE529444T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17965894A 1994-01-11 1994-01-11
US20826594A 1994-03-10 1994-03-10

Publications (1)

Publication Number Publication Date
ATE529444T1 true ATE529444T1 (de) 2011-11-15

Family

ID=26875521

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04022346T ATE529444T1 (de) 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
AT95908460T ATE277081T1 (de) 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95908460T ATE277081T1 (de) 1994-01-11 1995-01-11 Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten

Country Status (10)

Country Link
US (11) US6010880A (de)
EP (2) EP1489097B1 (de)
JP (5) JP4137997B2 (de)
AT (2) ATE529444T1 (de)
CA (1) CA2180954C (de)
DE (1) DE69533544T2 (de)
DK (2) DK1489097T3 (de)
ES (2) ES2229236T3 (de)
PT (2) PT737207E (de)
WO (1) WO1995018830A2 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP1489097B1 (de) 1994-01-11 2011-10-19 Dyax Corporation Inhibitoren des Humanplasmins, die sich von den Kunitz Domänen ableiten
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
ATE239501T1 (de) * 1995-06-07 2003-05-15 Chiron Corp Regulierung der neutrophil elastase synthese und freisetzung
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DE69735996T2 (de) 1996-03-11 2007-02-15 Bayer Corp. Menschlicher bikunin
ATE397061T1 (de) * 1997-01-08 2008-06-15 Invitrogen Corp Verfahren zur herstellung von proteinen
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20060025329A1 (en) * 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20020076728A1 (en) * 1997-03-21 2002-06-20 Maclennan John Moore Engineering affinity ligands for macromolecules
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6380354B1 (en) 1998-09-03 2002-04-30 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US5994310A (en) * 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
CA2342072C (en) * 1998-09-03 2005-01-11 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20030032146A1 (en) * 2001-07-10 2003-02-13 Dwulet Francis Edward Enzyme/tag binding and detection system
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
NZ579419A (en) * 2002-02-07 2011-02-25 Dyax Corp Albumin-fused kunitz domain peptides
PT1531791E (pt) * 2002-06-07 2010-12-16 Dyax Corp Prevenção e redução da isquémia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
AU2004204095B2 (en) * 2003-01-07 2009-07-30 Dyax Corporation Kunitz domain library
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005021556A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7740973B2 (en) * 2004-08-05 2010-06-22 General Motors Corporation Modular electrochemical power system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060111296A1 (en) * 2004-11-22 2006-05-25 Dyax Corp. Plasmin-inhibitory therapies
EP1858542A4 (de) 2005-02-24 2009-08-19 Joslin Diabetes Center Inc Zusammensetzungen und verfahren zur behandlung von gefässpermeabilität
GB0521404D0 (en) * 2005-10-20 2005-11-30 Ares Trading Sa Kunitz domain containing protein
WO2007070372A2 (en) * 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
AU2013202021B2 (en) * 2005-12-29 2016-03-10 The Regents Of The University Of California Methods and compositions related to mutant Kunitz domain of TFPI-2
JP5770966B2 (ja) * 2005-12-29 2015-08-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｆｐｉ−２の変異体クニッツドメインｉに関連した方法および組成物
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
EP1981538B1 (de) 2005-12-30 2014-09-17 Dyax Corporation Metalloproteinasebindende proteine
BRPI0708687A2 (pt) * 2006-03-08 2011-06-07 Bayer Healthcare Ag domìnios de kunitz quiméricos e seu uso
EP2001500A4 (de) * 2006-03-10 2010-07-28 Dyax Corp Formulierungen für ecallantid
PT1854477T (pt) * 2006-03-16 2016-11-10 Dyax Corp Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas
DK2374472T3 (en) 2006-03-16 2018-08-13 Dyax Corp Compositions and Methods for the Treatment of Eye Disorders
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
EP2195010A4 (de) * 2007-08-21 2012-03-14 Genzyme Corp Behandlung mit kallikrein-inhibitoren
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
WO2009030464A2 (de) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
JP5840494B2 (ja) 2008-10-02 2016-01-06 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ８６アンタゴニストの多標的結合タンパク質
CN102292352A (zh) * 2008-10-10 2011-12-21 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
CA2744235A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
CN103124743A (zh) 2009-12-29 2013-05-29 新兴产品开发西雅图有限公司 Ron结合构建物及其使用方法
ES2688093T3 (es) * 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
EP2827883B1 (de) 2012-03-21 2019-05-08 Baxalta GmbH Tfpi inhibitoren und deren verwendung
US10202452B2 (en) 2012-04-20 2019-02-12 Aptevo Research And Development Llc CD3 binding polypeptides
ES2813867T3 (es) * 2012-08-08 2021-03-25 Daiichi Sankyo Co Ltd Biblioteca de péptidos y su uso
EP2971039B1 (de) 2013-03-14 2020-01-01 Immusoft Corporation Verfahren zur in-vitro-speicher-b-zellen-differenzierung und -transduktion mit vsv-g-pseudotypisierten viralen vektoren
CN105377888A (zh) * 2013-03-15 2016-03-02 加利福尼亚大学董事会 纤维蛋白溶解的双反应性的有效的Kunitz抑制剂
DK3027204T3 (da) 2013-07-29 2022-04-19 2Seventy Bio Inc Flerdelte signaleringsproteiner og anvendelser deraf
NZ719840A (en) 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
HUE052573T2 (hu) 2013-12-20 2021-05-28 Hutchinson Fred Cancer Res Jelölt kiméra effektormolekulák és receptoraik
BR112016022318A2 (pt) 2014-03-27 2017-10-31 Dyax Corp método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
ES2929570T3 (es) 2014-12-19 2022-11-30 Immusoft Corp Células B para administración in vivo de agentes terapéuticos
RU2755227C2 (ru) 2015-03-05 2021-09-14 Фред Хатчинсон Кансэр Рисёч Сентер Иммуномодулирующие слитые белки и пути их применения
JP6985934B2 (ja) 2015-04-29 2021-12-22 フレッド ハッチンソン キャンサー リサーチ センター 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
AU2017250295B2 (en) 2016-04-14 2022-08-25 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP4269594A3 (de) 2017-02-17 2023-12-20 Fred Hutchinson Cancer Center Kombinationstherapien zur behandlung von bcma-bedingten krebsarten und autoimmunerkrankungen
AU2018236461A1 (en) 2017-03-17 2019-09-19 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
JP7431735B2 (ja) 2017-12-14 2024-02-15 ２セブンティ バイオ インコーポレイテッド Ｄａｒｉｃインターロイキン受容体
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN114729383A (zh) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 重组ad35载体及相关基因疗法改进
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
CA3181963A1 (en) 2020-05-04 2021-11-11 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
ES2066033T3 (es) * 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5278285A (en) 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
JPH0584083A (ja) 1990-11-13 1993-04-06 Mochida Pharmaceut Co Ltd 新規ポリペプチド、それをコードする新規ｄｎａ、新規ポリペプチドの製造方法、新規医薬組成物、および新規酵素阻害方法
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
DE69209390D1 (de) * 1991-06-28 1996-05-02 Wecotec Ltd Überführung von Tüchern
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL107831A0 (en) * 1992-12-02 1994-05-30 Zymogenetics Inc Novel human amyloid protein precursor homolog and kunitz-type inhibitor
CA2170030A1 (en) 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP1489097B1 (de) 1994-01-11 2011-10-19 Dyax Corporation Inhibitoren des Humanplasmins, die sich von den Kunitz Domänen ableiten
JP3805785B2 (ja) 1994-01-11 2006-08-09 ダイアックス コープ． カリクレイン阻害クニッツドメイン蛋白質およびその相同体
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
CA2229435A1 (en) 1995-09-14 1997-03-20 Lxr Biotechnology Inc. Compositions with anti-apoptotic activity, containing a mixture of phospholipids
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
EP0890638A4 (de) 1996-01-08 2001-08-22 Nissin Food Products Ltd Inhibitor von krebsmetastasen.
JP3357807B2 (ja) * 1997-01-13 2002-12-16 株式会社東芝 受信装置および移相器
US7383135B1 (en) * 1998-05-04 2008-06-03 Vertex Pharmaceuticals Incorporated Methods of designing inhibitors for JNK kinases
JP2000106882A (ja) 1998-10-02 2000-04-18 Chemo Sero Therapeut Res Inst 癌転移増殖抑制作用を有する血漿蛋白断片産生酵素および当該酵素により断片化された血漿蛋白断片
EP1243276A1 (de) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Langgestreckte und mehrfachige Abstandhaltern enthaltende aktivierbare Prodroge
IL159015A0 (en) 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
NZ579419A (en) 2002-02-07 2011-02-25 Dyax Corp Albumin-fused kunitz domain peptides
PT1531791E (pt) 2002-06-07 2010-12-16 Dyax Corp Prevenção e redução da isquémia
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
AU2004204095B2 (en) * 2003-01-07 2009-07-30 Dyax Corporation Kunitz domain library
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors

Also Published As

Publication number Publication date
EP0737207A1 (de) 1996-10-16
CA2180954A1 (en) 1995-07-13
US20030165896A1 (en) 2003-09-04
US20090036366A1 (en) 2009-02-05
DE69533544D1 (de) 2004-10-28
JP2012111779A (ja) 2012-06-14
US6103499A (en) 2000-08-15
PT1489097E (pt) 2012-01-04
WO1995018830A3 (en) 1995-08-10
US20110152193A1 (en) 2011-06-23
US20050186649A1 (en) 2005-08-25
US8431359B2 (en) 2013-04-30
US6010880A (en) 2000-01-04
JPH09509048A (ja) 1997-09-16
US6423498B1 (en) 2002-07-23
JP2013249302A (ja) 2013-12-12
ATE277081T1 (de) 2004-10-15
US6071723A (en) 2000-06-06
EP1489097A1 (de) 2004-12-22
US6953674B2 (en) 2005-10-11
US20080182283A1 (en) 2008-07-31
EP0737207B1 (de) 2004-09-22
EP1489097B1 (de) 2011-10-19
JP2008113657A (ja) 2008-05-22
DK0737207T3 (da) 2005-01-31
US20090036365A1 (en) 2009-02-05
JP2009183281A (ja) 2009-08-20
ES2375561T3 (es) 2012-03-02
US7919462B2 (en) 2011-04-05
WO1995018830A2 (en) 1995-07-13
DK1489097T3 (da) 2012-01-09
US20090023651A1 (en) 2009-01-22
CA2180954C (en) 2007-03-20
JP4137997B2 (ja) 2008-08-20
PT737207E (pt) 2005-02-28
DE69533544T2 (de) 2006-02-23
ES2229236T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
DE69533544D1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
EP1484339A3 (de) Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure
ATE239079T1 (de) Gewebeinhibitor für metalloproteasen type 3 (timp-3)
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
DE68929430D1 (de) Fibronektin bindendes Protein
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0817851T3 (da) DNA, der koder for humant papillomvirus type 18
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
SE9602822D0 (sv) New receptor
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
WO2001064876A3 (en) Human schizophrenia gene
DE69529235T2 (de) Menschliche dnase i varianten
SE9604439D0 (sv) New receptor
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1489097

Country of ref document: EP